Annovis Bio (ANVS) announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain ...
Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative ...
Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer's and Parkinson's. The company is developing innovative therapies that ...
Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Annovis Bio (ANVS – Research Report), retaining the price target of ...
Annovis Bio (ANVS) stock slipped after the company said the FDA accepted its updated protocol for a Phase 3 trial for its ...
In recent trading, Annovis Bio Inc (ANVS) stock price has shown some volatility, fluctuating -0.59% over the last five trades and -13.2 ...
Annovis Bio (ANVS) announced that the FDA has accepted an updated protocol for the pivotal Phase 3 Alzheimer’s Disease study, which is slated ...
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has announced that the U.S. Food and Drug Administration (FDA) has accepted an ...
Editas Medicine, Inc. (NASDAQ: EDIT) incurred a loss of 82 cents per share in the second quarter of 2024, wider than the Zacks Consensus Estimate of a loss of 69 cents. The company had reported a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback